CoChat
Sign Up
Cited by 461Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCNS Lymphoma Diagnosis and Treatment

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Open access
Wang, Michael, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Casasnovas, Olivier, Smith, Stephen D, Damaj, Gandhi, Doorduijn, Jeanette, Lamy, Thierry, Morschhauser, Franck, Panizo, Carlos, Shah, Bijal, Davies, Andrew, Eek, Richard, Dupuis, Jehan, Jacobsen, Eric, Kater, Arnon P, Le Gouill, Steven, Oberic, Lucie, Robak, Taduesz, Covey, Todd, Dua, Richa, Hamdy, Ahmed, Huang, Xin, Izumi, Raquel, Patel, Priti, Rothbaum, Wayne, Slatter, J Greg, Jurczak, Wojciech·2018·The Lancet
DOI 10.1016/s0140-6736(17)33108-2PMC PMC7864374
Open this paper in CoChat — free account

Abstract

Background Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.Methods In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity. The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants. This trial is registered with ClinicalTrials.gov, number NCT02213926.Findings From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years. Patients received a median of two (IQR 1-2) previous therapies. At a median follow-up of 15·2 months, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response. The Kaplan-Meier estimated medians for duration of response, progression-free survival, and overall survival were not reached; the 12-month rates were 72% (95% CI 62-80), 67% (58-75), and 87% (79-92%), respectively. The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]). The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]). There were no cases of atrial fibrillation and one case of grade 3 or worse haemorrhage. The median duration of treatment was 13·8 months. Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]).Interpretation Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. These findings suggest an important role for acalabrutinib in the treatment of this disease population.Funding Acerta Pharma, a member of the AstraZeneca Group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)33108-2

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

Sorted by citations

Items 301–400 of 461

Related

See all

Metadata

Authors
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., Le Gouill, S., Oberic, L., Robak, T., Covey, T., Dua, R., Hamdy, A., Huang, X., Izumi, R., Patel, P., Rothbaum, W., Slatter, J. G., & Jurczak, W.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Plymouth (GB)
  • University of Bologna (IT)
  • Hackensack University Medical Center (US)
  • Inserm (FR)
  • University of Washington (US)
  • Centre Hospitalier Universitaire de Caen Normandie (FR)
  • Erasmus MC (NL)
  • Centre Hospitalier Universitaire de Rennes (FR)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Clinica Universidad de Navarra (ES)
  • Moffitt Cancer Center (US)
  • Cancer Research UK (GB)
  • Centre Hospitalier Universitaire Henri-Mondor (FR)
  • Harvard University (US)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Jagiellonian University (PL)
Corresponding author
Wang, Michael
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-02
Volume
391
Issue
10121
Pages
659-667
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(17)33108-2
PMC
PMC7864374
OpenAlex
W2774522106
Cited by
453
References
23
Citations by year
2026: 39 · 2025: 31 · 2024: 51 · 2023: 49 · 2022: 59 · 2021: 60 · 2020: 63 · 2019: 64 · 2018: 34
FWCI
34.80
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • PEARL (University of Plymouth) (submittedVersion, other-oa)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
  • Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • HAL (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • PEARL (University of Plymouth) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Funders
  • AstraZeneca
  • University of Texas MD Anderson Cancer Center
  • National Cancer Institute (P30CA076292)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
Keywords
acalabrutinib, mantle cell lymphoma, relapsed/refractory lymphoma, BTK inhibitors, overall response rate, complete response, progression-free survival, overall survival, adverse events, neutropenia, drug safety, oral targeted therapy, treatment durability, hemorrhage
MeSH terms
Aged, Benzamides, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pyrazines, Recurrence, Survival Analysis, Treatment Outcome, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review